Stock comparison
Exelixis
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
EXEL
Exelixis
Market cap
$12.61B
Sector
Healthcare
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | EXEL | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 64C | 72B | LLY |
| Benjamin Graham | 74B | 86A | LLY |
| Philip Fisher | 74B | 86A | LLY |
| Peter Lynch | 58C | 74B | LLY |
| Joel Greenblatt | 60C | 78C | LLY |
| Charlie Munger | 71B | 85A | LLY |
| Terry Smith | 80A | 77C | EXEL |
Side-by-side metrics
| Metric | EXEL | LLY |
|---|---|---|
| Market cap | $12.61B | $1T |
| P/E (TTM) | 15.3x | 36.6x |
| EV/EBIT | 14.2x | 34.1x |
| ROIC (TTM) | 35.01% | 32.06% |
| Gross margin | 96.44% | 83.51% |
| Net margin | 35.08% | 34.98% |
| Revenue CAGR 5y | 12.76% | 23.17% |
| EPS CAGR 5y | 40.93% | 40.81% |
| Debt / Equity | 0.1x | 1.4x |
| Dividend yield | 0.0% | 0.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
EXEL leads on
- Debt / Equity0.1xvs 1.4x+94%
- EV/EBIT14.2xvs 34.1x+58%
- P/E (TTM)15.3xvs 36.6x+58%
- Gross margin96.44%vs 83.51%+13%
LLY leads on
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $12.61B+99%
- Revenue CAGR 5y23.17%vs 12.76%+45%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.